{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:12:51Z","timestamp":1785521571082,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00405-026-10295-9","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T20:51:57Z","timestamp":1778532717000},"page":"5263-5273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimation of the indirect costs associated with chronic rhinosinusitis with nasal polyposis in Spain: an analysis from a societal perspective"],"prefix":"10.1007","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3588-9095","authenticated-orcid":false,"given":"Juan","family":"Maza-Solano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5757-7040","authenticated-orcid":false,"given":"Guillermo","family":"San-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4332-0920","authenticated-orcid":false,"given":"Alfonso","family":"Cuvillo-Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3580-0967","authenticated-orcid":false,"given":"Christian","family":"Calvo-Henriquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-4537","authenticated-orcid":false,"given":"Sandra","family":"Dom\u00ednguez-Sosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-5513","authenticated-orcid":false,"given":"Ignacio","family":"D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6664-0276","authenticated-orcid":false,"given":"Ruperto","family":"Gonz\u00e1lez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1321-007X","authenticated-orcid":false,"given":"Jos\u00e9 Miguel","family":"Villacampa-Aub\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7204-5599","authenticated-orcid":false,"given":"Isam","family":"Alobid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"3","key":"10295_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4193\/Rhin23.415","volume":"62","author":"WJ Fokkens","year":"2024","unstructured":"Fokkens WJ, De Corso E, Backer V, Bernal-Sprekelsen M, Bjermer L, von Buchwald C et al (2024) EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP. Rhinology 62(3):287\u2013298. https:\/\/doi.org\/10.4193\/Rhin23.415","journal-title":"Rhinology"},{"issue":"5","key":"10295_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.18176\/jiaci.0910","volume":"33","author":"I Alobid","year":"2023","unstructured":"Alobid I, Col\u00e1s C, Castillo JA, Arismendi E, Del Cuvillo A, G\u00f3mez-Outes A et al (2023) Spanish Consensus on the Management of Chronic Rhinosinusitis With Nasal Polyps (POLIposis NAsal\/POLINA 2.0). J Investig Allergol Clin Immunol 33(5):317\u2013331. https:\/\/doi.org\/10.18176\/jiaci.0910","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"10295_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/healthcare13040430","volume":"13","author":"L Malvezzi","year":"2025","unstructured":"Malvezzi L, Seccia V, Moffa A, Canevari FRM, Baiardini I, Barbaglia S et al (2025) The Impact and Burden of Chronic Rhinosinusitis with Nasal Polyps on Patients and Their Family Caregivers: A Nationally Representative Survey. Healthc (Basel) 13(4):430. https:\/\/doi.org\/10.3390\/healthcare13040430","journal-title":"Healthc (Basel)"},{"issue":"3","key":"10295_CR4","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3390\/jcm13030866","volume":"13","author":"D Martin-Jimenez","year":"2024","unstructured":"Martin-Jimenez D, Moreno-Luna R, Callejon-Leblic A, Del Cuvillo A, Ebert CS, Maza-Solano J et al (2024) Long-Term Clinical Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps Associated with Expanded Types of Endoscopic Sinus Surgery. J Clin Med 13(3):866. https:\/\/doi.org\/10.3390\/jcm13030866","journal-title":"J Clin Med"},{"issue":"4","key":"10295_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2500\/ajra.2017.31.4452","volume":"31","author":"J Yip","year":"2017","unstructured":"Yip J, Vescan AD, Witterick IJ, Monteiro E (2017) The personal financial burden of chronic rhinosinusitis: A Canadian perspective. Am J Rhinol Allergy 31(4):216\u2013221. https:\/\/doi.org\/10.2500\/ajra.2017.31.4452","journal-title":"Am J Rhinol Allergy"},{"key":"10295_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/JAA.S86251","volume":"9","author":"J Mullol","year":"2016","unstructured":"Mullol J, Langdon C (2016) Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy 9:45\u201353. https:\/\/doi.org\/10.2147\/JAA.S86251","journal-title":"J Asthma Allergy"},{"issue":"9","key":"10295_CR7","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1002\/lary.27852","volume":"129","author":"N Bhattacharyya","year":"2019","unstructured":"Bhattacharyya N, Villeneuve S, Joish VN, Amand C, Mannent L, Amin N et al (2019) Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope 129(9):1969\u20131975. https:\/\/doi.org\/10.1002\/lary.27852","journal-title":"Laryngoscope"},{"issue":"5","key":"10295_CR8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.4193\/Rhin24.147","volume":"62","author":"T Mora","year":"2024","unstructured":"Mora T, S\u00e1nchez-Collado I, Mu\u00f1oz-Cano R, Rib\u00f3 P, Mullol J, Valero A (2024) Differential healthcare direct costs of asthma and chronic rhinosinusitis with nasal polyps in Catalonia (Spain). Rhinology 62(5):590\u2013596. https:\/\/doi.org\/10.4193\/Rhin24.147","journal-title":"Rhinology"},{"issue":"1","key":"10295_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.otc.2022.09.001","volume":"56","author":"W Fokkens","year":"2023","unstructured":"Fokkens W, Reitsma S (2023) Unified Airway Disease: A Contemporary Review and Introduction. Otolaryngol Clin North Am 56(1):1\u201310. https:\/\/doi.org\/10.1016\/j.otc.2022.09.001","journal-title":"Otolaryngol Clin North Am"},{"issue":"5","key":"10295_CR10","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00405-022-07762-4","volume":"280","author":"J Maza-Solano","year":"2023","unstructured":"Maza-Solano J, Biadsee A, Sowerby LJ, Calvo-Hern\u00e1ndez C, Tucciarone M, Rocha T et al (2023) Chronic rhinosinusitis with nasal polyps management in the biologic therapy era: an international YO-IFOS survey. Eur Arch Otorhinolaryngol 280(5):2309\u20132316. https:\/\/doi.org\/10.1007\/s00405-022-07762-4","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10295_CR11","doi-asserted-by":"publisher","unstructured":"Augustovski F, Garc\u00eda Mart\u00ed S, Espinoza MA, Palacios A, Husereau D, Pichon-Riviere A (2022) Est\u00e1ndares Consolidados de Reporte de Evaluaciones Econ\u00f3micas Sanitarias: adaptaci\u00f3n al espa\u00f1ol de la lista de comprobaci\u00f3n CHEERS 2022. Value Health Reg Issues 27:110\u2013114. https:\/\/doi.org\/10.1016\/j.vhri.2021.11.001","DOI":"10.1016\/j.vhri.2021.11.001"},{"key":"10295_CR12","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta Anual de Estructura Salarial (EAES) (2023) Datos definitivos [Internet]. Madrid: INE; 2025 [citado 1 dic 2025]. Disponible en: https:\/\/www.ine.es\/dyngs\/Prensa\/EAES2023.htm"},{"issue":"4","key":"10295_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.4193\/Rhin23.341","volume":"62","author":"J Mullol","year":"2024","unstructured":"Mullol J, Sastre J, Dominguez-Ortega J, Blanco-Aparicio M, Castillo Vizuete JA, Alobid I et al (2024) Prevalence of chronic rhinosinusitis without\/with nasal polyps according to severity in Spain. Rhinology 62(4):421\u2013431. https:\/\/doi.org\/10.4193\/Rhin23.341","journal-title":"Rhinology"},{"issue":"5","key":"10295_CR14","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4193\/Rhin21.364","volume":"60","author":"I Sanchez-Collado","year":"2022","unstructured":"Sanchez-Collado I, Mora T, Munoz-Cano R, Ribo P, Mullol J, Valero A (2022) Prevalence of Chronic Rhinosinusitis with Nasal Polyps in Catalonia (Spain): a retrospective, large-scale population-based study. Rhinology 60(5):384\u2013396. https:\/\/doi.org\/10.4193\/Rhin21.364","journal-title":"Rhinology"},{"issue":"9","key":"10295_CR15","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/lary.24630","volume":"124","author":"L Rudmik","year":"2014","unstructured":"Rudmik L, Smith TL, Schlosser RJ, Hwang PH, Mace JC, Soler ZM (2014) Productivity costs in patients with refractory chronic rhinosinusitis. Laryngoscope 124(9):2007\u20132012. https:\/\/doi.org\/10.1002\/lary.24630","journal-title":"Laryngoscope"},{"issue":"3","key":"10295_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/alr.23070","volume":"13","author":"VC Pandrangi","year":"2023","unstructured":"Pandrangi VC, Mace JC, Kim JH, Geltzeiler M, Detwiller KY, Soler ZM et al (2023) Work productivity and activity impairment in patients with chronic rhinosinusitis undergoing endoscopic sinus surgery-A prospective, multi-institutional study. Int Forum Allergy Rhinol 13(3):216\u2013229. https:\/\/doi.org\/10.1002\/alr.23070","journal-title":"Int Forum Allergy Rhinol"},{"issue":"Suppl 1","key":"10295_CR17","doi-asserted-by":"publisher","first-page":"i89","DOI":"10.1136\/ard.2009.117150","volume":"69","author":"WB van den Hout","year":"2010","unstructured":"van den Hout WB (2010) The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 69(Suppl 1):i89\u201391. https:\/\/doi.org\/10.1136\/ard.2009.117150","journal-title":"Ann Rheum Dis"},{"key":"10295_CR18","doi-asserted-by":"publisher","unstructured":"Lensberg BR, Drummond MF, Danchenko N, Despi\u00e9gel N, Fran\u00e7ois C (2013) Challenges in measuring and valuing productivity costs, and their relevance in mood disorders. Clinicoecon Outcomes Res 5:565\u2009\u2013\u200973. https:\/\/doi.org\/10.2147\/CEOR.S44866","DOI":"10.2147\/CEOR.S44866"},{"issue":"11","key":"10295_CR19","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1111\/all.14408","volume":"75","author":"SF Seys","year":"2020","unstructured":"Seys SF, De Bont S, Fokkens WJ, Bachert C, Alobid I, Bernal-Sprekelsen M et al (2020) Real-life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA. Allergy 75(11):2867\u20132878. https:\/\/doi.org\/10.1111\/all.14408","journal-title":"Allergy"},{"issue":"6","key":"10295_CR20","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.jaip.2022.01.039","volume":"10","author":"PW Hellings","year":"2022","unstructured":"Hellings PW (2022) SWOT Analysis of Chronic Rhinosinusitis Care Anno 2022. J Allergy Clin Immunol Pract 10(6):1468\u20131471. https:\/\/doi.org\/10.1016\/j.jaip.2022.01.039","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10295_CR21","doi-asserted-by":"publisher","first-page":"CD013513","DOI":"10.1002\/14651858.CD013513.pub3","volume":"3","author":"LY Chong","year":"2021","unstructured":"Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C et al (2021) Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev 3(3):CD013513. https:\/\/doi.org\/10.1002\/14651858.CD013513.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"10209","key":"10295_CR22","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638\u20131650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"issue":"5","key":"10295_CR23","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/all.16499","volume":"80","author":"S Cai","year":"2025","unstructured":"Cai S, Xu S, Zhao Y, Zhang L (2025) Efficacy and Safety of Biologics for Chronic Rhinosinusitis With Nasal Polyps: A Meta-Analysis of Real-World Evidence. Allergy 80(5):1256\u20131270. https:\/\/doi.org\/10.1111\/all.16499","journal-title":"Allergy"},{"issue":"12","key":"10295_CR24","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","volume":"392","author":"BJ Lipworth","year":"2025","unstructured":"Lipworth BJ, Han JK, Desrosiers M, Hopkins C, Lee SE, Mullol J et al (2025) Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. N Engl J Med 392(12):1178\u20131188. https:\/\/doi.org\/10.1056\/NEJMoa2414482","journal-title":"N Engl J Med"},{"issue":"1","key":"10295_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s40273-020-00986-4","volume":"39","author":"A Yuasa","year":"2021","unstructured":"Yuasa A, Yonemoto N, LoPresti M, Ikeda S (2021) Use of Productivity Loss\/Gain in Cost-Effectiveness Analyses for Drugs: A Systematic Review. PharmacoEconomics 39(1):81\u201397. https:\/\/doi.org\/10.1007\/s40273-020-00986-4","journal-title":"PharmacoEconomics"},{"key":"10295_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1471-2466-9-24","volume":"9","author":"K Bahadori","year":"2009","unstructured":"Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J et al (2009) Economic burden of asthma: a systematic review. BMC Pulm Med 9:24. https:\/\/doi.org\/10.1186\/1471-2466-9-24","journal-title":"BMC Pulm Med"},{"key":"10295_CR27","unstructured":"Puig-Junoy J, Pascual-Argent\u00e9 N (2017) Costes socioecon\u00f3micos del asma en la Uni\u00f3n Europea, Estados Unidos y Canad\u00e1: revisi\u00f3n sistem\u00e1tica [Socioeconomic Costs of Asthma in the European Union, United States and Canada: A Systematic Review]. Rev Esp Salud Publica 91:e201703025. Spanish"},{"issue":"10","key":"10295_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.arbres.2009.04.006","volume":"45","author":"E Mart\u00ednez-Morag\u00f3n","year":"2009","unstructured":"Mart\u00ednez-Morag\u00f3n E, Serra-Batll\u00e9s J, De Diego A, Palop M, Casan P, Rubio-Terr\u00e9s C et al (2009) Coste econ\u00f3mico del paciente asm\u00e1tico en Espa\u00f1a (estudio AsmaCost). Arch Bronconeumol 45(10):481\u2013486. https:\/\/doi.org\/10.1016\/j.arbres.2009.04.006. Spanish","journal-title":"Arch Bronconeumol"},{"key":"10295_CR29","doi-asserted-by":"publisher","first-page":"106670","DOI":"10.1016\/j.rmed.2021.106670","volume":"191","author":"A Czira","year":"2022","unstructured":"Czira A, Turner M, Martin A, Hinds D, Birch H, Gardiner F et al (2022) A systematic literature review of burden of illness in adults with uncontrolled moderate\/severe asthma. Respir Med 191:106670. https:\/\/doi.org\/10.1016\/j.rmed.2021.106670","journal-title":"Respir Med"},{"issue":"2","key":"10295_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.otc.2023.09.007","volume":"57","author":"KB Patel","year":"2024","unstructured":"Patel KB, Mims JW, Clinger JD (2024) The Burden of Asthma and Allergic Rhinitis: Epidemiology and Health Care Costs. Otolaryngol Clin North Am 57(2):179\u2013189. https:\/\/doi.org\/10.1016\/j.otc.2023.09.007","journal-title":"Otolaryngol Clin North Am"},{"issue":"6","key":"10295_CR31","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/all.13099","volume":"72","author":"C Col\u00e1s","year":"2017","unstructured":"Col\u00e1s C, Brosa M, Ant\u00f3n E, Montoro J, Navarro A, Dordal MT et al (2017) Estimate of the total costs of allergic rhinitis in specialized care based on real-world data: the FERIN Study. Allergy 72(6):959\u2013966. https:\/\/doi.org\/10.1111\/all.13099","journal-title":"Allergy"},{"issue":"6","key":"10295_CR32","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1111\/all.16596","volume":"80","author":"I Agache","year":"2025","unstructured":"Agache I, Torres M, Eguiluz-Gracia I, Bradatan E, El Abd K, Bilo MB et al (2025) Economic Impact of Allergic Diseases and Asthma-The HEAD Pan-European Registry. Allergy 80(6):1677\u20131701. https:\/\/doi.org\/10.1111\/all.16596","journal-title":"Allergy"},{"issue":"3","key":"10295_CR33","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4193\/Rhin19.468","volume":"58","author":"ES Lourijsen","year":"2020","unstructured":"Lourijsen ES, Fokkens WJ, Reitsma S (2020) Direct and indirect costs of adult patients with chronic rhinosinusitis with nasal polyps. Rhinology 58(3):213\u2013217. https:\/\/doi.org\/10.4193\/Rhin19.468","journal-title":"Rhinology"},{"issue":"11","key":"10295_CR34","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1080\/03007995.2020.1815683","volume":"36","author":"S Chen","year":"2020","unstructured":"Chen S, Zhou A, Emmanuel B, Garcia D, Rosta E (2020) Systematic literature review of humanistic and economic burdens of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin 36(11):1913\u20131926. https:\/\/doi.org\/10.1080\/03007995.2020.1815683","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10295_CR35","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/alr.22976","volume":"12","author":"VK Rathi","year":"2022","unstructured":"Rathi VK, Scangas GA, Metson RB, Xiao R, Nshuti L, Dusetzina SB (2022) Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. Int Forum Allergy Rhinol 12(10):1295\u20131298. https:\/\/doi.org\/10.1002\/alr.22976","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10295-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-026-10295-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10295-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:03:52Z","timestamp":1785517432000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-026-10295-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10295"],"URL":"https:\/\/doi.org\/10.1007\/s00405-026-10295-9","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"16 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JMS has received honoraria for consultancy, research projects, advisory board participation, and lectures from AstraZeneca, GlaxoSmithKline, MSD, Novartis, and Sanofi-Regeneron.GSG declares no conflicts of interest.CCH has received honoraria for consultancy and conference participation from Sanofi-Regeneron, AstraZeneca, GSK, MSD, Cinfa, and Forwardontics.SDS has received fees from GSK, Sanofi-Regeneron, MSD, and MEDA for lectures at scientific meetings and serves on advisory boards.AC, over the past three years, has received consultancy fees from AstraZeneca, Sanofi-Regeneron, GSK, MSD, Menarini, and Meda; speaker fees and payments for presentations and educational activities from AstraZeneca, Sanofi-Regeneron, GSK, MSD, Regeneron, Menarini, and Meda; expert testimony fees from Sanofi-Regeneron, GSK, AstraZeneca, and Menarini; and travel grants and congress attendance support from Sanofi-Regeneron, Menarini, and FAES. AC also serves as President of the Rhinology, Allergy, and Anterior Skull Base Committee of the Spanish Society of Otorhinolaryngology and Head and Neck Surgery.ID, over the past three years, has received speaker fees from Allergy Therapeutics, AstraZeneca, Chiesi, Diater, GSK, Leti, Novartis, and Sanofi-Regeneron; consultancy fees from AstraZeneca, GSK, Merck, MSD, Novartis, and Sanofi-Regeneron; and competitive project funding from Thermo Fisher Diagnostics, Sanofi-Regeneron, the Instituto de Salud Carlos III (ISCIII), and the Regional Government of Castilla y Le\u00f3n.RGP has received honoraria for consultancy, research projects, advisory board participation, and lectures from GSK, AstraZeneca, Inmunotek, Diater, LETI, Sanofi-Regeneron, and Menarini.JVA has received honoraria for consultancy, research projects, advisory board participation, and lectures from AstraZeneca, GlaxoSmithKline, MSD, Novartis, Medtronic, and Sanofi-Regeneron.IA has received honoraria for consultancy, research projects, advisory board participation, and lectures from GSK, AstraZeneca, MSD, Novartis Salvat, Medtronic, Storz, Olympus, and Sanofi-Regeneron.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}